Patents Assigned to INSERM (Institut National de la Santé et de la Recherche Médicale)
  • Patent number: 10969391
    Abstract: The present invention relates to methods for diagnosing hematological cancers. In particular, the present invention relates to a method for diagnosing a hematological cancer in a patient comprising i) detecting the presence of CD45RARO NK cells in a sample obtained from the patient and ii) and concluding that the patient suffers from a hematological cancer when the presence of CD45RARO NK cells is detected in the sample and the presence of at least one phenotypic marker indicates the nature of the haematological cancer.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: April 6, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Martin Villalba Gonzalez, Ewelina Krzywinska
  • Patent number: 10961580
    Abstract: The invention relates to a method for predicting graft alterations in a transplanted patient, comprising a step of determining the expression levels of bactericidal/permeability-increasing protein (BPI), chemokine (C motif) ligand 1 (XCL1) and thioredoxin domain containing 3 (TXNDC3) genes in a biological sample obtained from said transplanted patient.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: March 30, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Nantes, Centre Hospitalier Universitaire de Nantes
    Inventors: Sophie Brouard, Magali Giral, Richard Danger
  • Patent number: 10962525
    Abstract: A process for characterizing a blood sample includes: insertion, into a channel with an inlet and outlet, of a solution including blood platelets, the solution being inserted via the inlet of the channel; creating a pressure difference between the inlet and the outlet to move the solution from the inlet towards the outlet of the channel; passage of the solution into a measurement zone of the channel, provided with electrodes; measurement, by the electrodes and measurement element, of an electric signal while the electrodes are covered by the solution in the channel. The progression of the solution from the inlet towards the outlet of the channel includes a progression of a front between, on the one hand, the solution extending from the front towards the inlet of the channel and, on the other hand, a gas extending from the front towards the outlet of the channel.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: March 30, 2021
    Assignees: SORBONNE UNIVERSITE, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, CONCEPTION DE SYSTEMES ET TECHNOLOGIE MECANIQUE: CSTM
    Inventors: Francine Rendu, Monique Dufilho, François Dugue
  • Patent number: 10954299
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections. The increasing burden of antimicrobial resistance coupled with the decreasing number of antibiotics in development has urged for strategies to elaborate new therapies. The inventors showed a therapeutic effect of IL-20 receptor 10 antagonists in pulmonary bacterial infection mouse model. Indeed, they demonstrated that treatment with IL-20 receptor antagonists reduces bacterial burden, cellular infiltration and inflammation in bronchoalveolar lavage fluid (BALF) and lung. In particular, the present invention relates to an antagonist of IL-20 cytokines, or/and an antagonist of IL-20RB receptor for use in a method for the treatment of pulmonary bacterial infections in a subject in 15 need thereof.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: March 23, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Centre National de la Recherche Scientifique (CNRS), Institut Paseur de Lille, Universitéde Lille
    Inventors: Philippe Gosset, Fahima Madouri, Muriel Pichavant
  • Patent number: 10947598
    Abstract: Provided is an in vitro method for determining the metabolic status of a lymphoma comprising a step of determining the level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression in lymphoma cells, wherein a low level of GAPDH expression is indicative of oxidative phosphorylation (OXPHOS) status. Also provided is an in vitro method for predicting the responsiveness of a patient afflicted with a lymphoma to a treatment with a metabolic inhibitor selected from the group consisting of mitochondrial metabolic inhibitors and glutamine metabolism inhibitors comprising a step of determining the level of GAPDH expression in lymphoma cells obtained from said patient, wherein a low level of GAPDH expression is predictive of a response to a treatment with a metabolic inhibitor.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: March 16, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), Université Côte d'Azur, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Jean-Ehrland Ricci, Johanna Chiche, Catherine Thieblemont
  • Patent number: 10947276
    Abstract: A method for delivering a cargo molecule into a cell is described that comprises linking a cargo molecule to a cell penetrating peptide. Chimeric constructs comprising cell penetrating moieties are also provided.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 16, 2021
    Assignees: SORBONNE UNIVERSITÉ, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, PEP-THERAPY
    Inventors: Angelita Rebollo, Jesus Maria Fominaya Gutierrez, Jeronimo Bravo Sicilia, Sophie Lebel Binay, Leticia Dominguez Berrocal
  • Patent number: 10918737
    Abstract: The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNF? blocking agent to a subject in combination with the immune checkpoint inhibitor.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: February 16, 2021
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III, Centre Hospitalier Universitaire de Toulouse
    Inventors: Thierry Levade, Bruno Segui, Nicolas Meyer, Céline Colacios Viatgé, Nathalie Andrieu-Abadie, Florie Bertrand
  • Publication number: 20210040204
    Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).
    Type: Application
    Filed: October 27, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Strasbourg, Chu Strasbourg, Les Hôpitaux Universitaires de Strasbourg
    Inventors: Thomas Baumert, Rajeevkumar Tawar
  • Publication number: 20210038691
    Abstract: The present invention relates to novel therapies for treating autoimmune and inflammatory diseases. More specifically, the present invention relates to a use of low dose interleukin-2 for the treatment of type I diabetes and other autoimmune and/or inflammatory diseases.
    Type: Application
    Filed: July 10, 2020
    Publication date: February 11, 2021
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, SORBONNE UNIVERSITE
    Inventors: David Klatzmann, David SAADOUN, Patrice CACOUB, Michèle ROSENZWAJG, Eliane PIAGGIO, Gilbert BENSIMON, Claude BERNARD
  • Publication number: 20210032607
    Abstract: The present invention relates to the prevention or treatment of skeletal growth retardation disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FG-FR3), in particular by expression of a constitutively activated mutant of FGFR3. More particularly, the present invention relates to a soluble FGFR3 for use in the prevention or treatment of achondroplasia.
    Type: Application
    Filed: March 13, 2020
    Publication date: February 4, 2021
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Université Paul Sabatier Toulouse III
    Inventor: Elvire Gouze
  • Publication number: 20210030703
    Abstract: In most cases, cancer chemotherapy and immunotherapy fail to yield durable responses, and complete and permanent regression of established tumors are rare. Here the inventors show that so-called caloric restriction mimetics (CRMs), which are natural or synthetic compounds that pharmacologically mimic the effects of fasting or caloric restriction, can be used to enhance the probability of cancer cure. The administration of several chemically distinct CRMs (such as hydroxycitrate, lipoic acid and the natural polyamine spermidine) led to the complete regression and the induction of protective anticancer immune responses in mouse models. This effect was achieved when CRMs were combined with chemotherapy and immunotherapy targeting the immune checkpoint molecules CTLA-4 and/or PD-1. Hence, caloric restriction and CRMs can be used to sensitize cancers to chemo-immunotherapy.
    Type: Application
    Filed: March 11, 2019
    Publication date: February 4, 2021
    Applicants: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ DE PARIS, SORBONNE UNIVERSITÉ, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP), UNIVERSITÉ PARIS-SACLAY
    Inventors: Guido KROEMER, Sarah LEVESQUE, Jonathan POL
  • Patent number: 10899816
    Abstract: The present invention relates to an immunocytokine comprising (a) a conjugate, and (b) an antibody or a fragment thereof directly or indirectly linked by covalence to said conjugate, wherein said conjugate comprises (i) a polypeptide comprising the amino acid sequence of the interleukin 15 or derivatives thereof, and (ii) a polypeptide comprising the amino acid sequence of the sushi domain of the interleukin 15R alpha (IL-15R?) or derivatives thereof; and uses thereof.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: January 26, 2021
    Assignees: INSERM (Institut National De La Santé Et De La Recherche Medicale), Cytune Pharma
    Inventors: Sebastien Daniel Morisseau, Geraldine Teppaz, Yannick Laurent Joseph Jacques, Bruno Gilbert Marc Robert, Guy Luc Michel De Martynoff, David Bechard
  • Publication number: 20210009657
    Abstract: The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia.
    Type: Application
    Filed: February 20, 2020
    Publication date: January 14, 2021
    Applicants: Pfizer Inc., INSERM (Institut National de la Sante et de la Recherche Medicale), Université Côte d'Azur
    Inventors: Elvire Gouze, Stéphanie Garcia
  • Patent number: 10874637
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of neurodegeneration in with brain iron accumulation (NBIA). Studying two novel genes, namely, CRAT encoding the carnitine acetyltransferase and REPS1 involved in endocytosis and vesicle transport, and a series of known NBIA genes, the inventors reported on iron overload related to increased levels and abnormal recycling of transferrin receptor as a common feature in NBIA. They ascribe this anomaly, at least in part, to impaired palmitoylation of the receptor as a common consequence of the various disease causing mutations. Finally, the inventors show that Artesunate improved TfR1 palmitoylation in NBIA fibroblasts. In particular, the present invention relates to a method of treating neurodegeneration with brain iron accumulation in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a drug increasing TfR1 palmitoylation.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: December 29, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DESCARTES, FONDATION IMAGING, ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
    Inventors: Anne Agnès Rötig, Anthony Drecourt
  • Patent number: 10857239
    Abstract: The invention relates to the use of HNRNPC-expressing vectors for preventing and/or treating a tauopathy, such as Alzheimer's disease. The invention relates to methods for detecting a risk of developing a tauopathy such Alzheimer's disease in a patient, comprising the step of detecting the level of HNRNPC in a biological sample obtained from said patient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: December 8, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)
    Inventors: Thierry Leveillard, Jose-Alain Sahel, Hawa Camara
  • Patent number: 10849943
    Abstract: The present invention relates to vaccine compositions comprising an attenuated mutant Zika virus. The inventors have introduced mutations at very specific positions that abrogate the N-glycosylation site on the E protein of the epidemic strain which will prevent the generation of auto-antibodies responsible for Guillain-Barre syndrome. The inventors have also produced additional mutations of the virus that result to a dramatic reduction of the cytopathic effects without affecting the capacity to produce high titers of virus. In particular, the present invention relates to an attenuated mutant Zika virus comprising a protein E of the epidemic strain wherein at least one amino acid residue at position 152, 156 or 158 is mutated.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: December 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LA REUNION SAINT DENIS, INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE-CNRS
    Inventors: Philippe Despres, Gilles Gadea, Patrick Mavingui, Wildriss Viranaicken
  • Patent number: 10851176
    Abstract: The present invention relates to a method and compositions for the treatment of haemorrhagic diseases.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: December 1, 2020
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT—PARIS 7, UNIVERSITE PARIS XIII PARIS-NORD
    Inventors: Marie-Christine Bouton, Petrus Lenting, Cécile Denis, Olivier Christophe
  • Publication number: 20200338062
    Abstract: The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.
    Type: Application
    Filed: May 14, 2020
    Publication date: October 29, 2020
    Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix-Marseille
    Inventor: Philippe Pierre
  • Patent number: 10815207
    Abstract: The present invention relates to compound of general formula (I) R1 is selected from H, aryl and alkyl, R2 is selected from H, alkyl, aryl and CO—R6; R3 is selected from H, halogen, alkyl, alkenyl, alkynyl, aryl, NHR7, NR7R8, OR7 and SR7; R4 is selected from (C6-C12) alkyl, (C2-C12) alkenyl, (C2-C12) alkynyl and (C6-C10) aryl, R5 represents H, R6, aryl, OH, OR6, O-aryl, SH, SR6, S-aryl, CN, NO2, CF3, COOR6, SO2NR6R7, CONR6R7, NH2, NHR6, NH-aryl, NR6R7, NHCOR6 or aminoacyl; R6 is alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di(alkyl); R7 and R8 identical or different are H or alkyl optionally substituted with halogen, OH, SH, NH2, O-alkyl, S-alkyl, NH-alkyl or NH-di (alkyl), their pharmaceutically acceptable salts and/or isomers, tautomers, solvates or isotopic variations thereof. The compounds are useful for the treatment of cancers.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: October 27, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite Nice Sophia Antipolis, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Stephane Rocchi, Rachid Benhida, Robert Ballotti, Magali Plaisant, Cyril Ronco, Antoine Millet
  • Patent number: 10807958
    Abstract: The present invention relates to the compound having Formula (I) or pharmaceutically acceptable salts or solvates thereof, and its use in treating and/or preventing a Tauopathy.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: October 20, 2020
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE LILLE 2 DROIT ET SANTE
    Inventors: Nicolas Sergeant, Luc Buee, Patricia Melnyk, Marion Gay, Nicolas Le Fur